TAF PUBLISHING

Severe Acute Respiratory Syndrome Corona Virus (SARS CoV2) is the etiology of COVID-19 that can cause severe disease in the young age group. In China, Covid-19's patients with mild-severe signs were 81% (including those without pneumonia and mild pneumonia), 14% with severe disease, and 5% with critical disease. COVID-19 infected people in 31-45 years old was 29, 3%, and the highest death could happen in old age at about 17, 68%. In Paser Regency, East Kalimantan, COVID-19’s patients were 2912, cured 2644 people, and died 58 people. Treatment of critical COVID-19’s patients was not good enough. It still limited data using antivirus, antibiotic, antiinflammation, anti thrombotic, and support agents. Another treatment was needed to increase the chance to live. It was convalescent plasma from cured people that would be given to symptomatic patients. This research’s goal was to analyze the effect of convalescent plasma to increase IgG and IgM level to prevention of death in COVID-19's ICU. Research’s design was quasy experimental. The intervention was convalescent plasma to COVID-19’s patients di ICU. The populations were 101 patients in Panglima Sebaya Hospital, Paser Regency. The samples were 50 patients. Independent variable was convalescent plasma. Dependent variables were blood IgG and IgM levels. Data analyzes used pair-T-Test if in a normal distribution and Wilcoxon test if not in a normal distribution. The result showed IgG level was 269,18 ± 217,341 before treatment and 1648,1 ± 490.140 after treatment ( p value = 0.000). IgM level was 78,06 ± 53.757 before treatment and 274,16 ± 160.908 after treatment (p value = 0.000). From all of the samples, 75% of them were cured, and the rest were dead. The conclusion was that convalescent plasma increased IgG and IgM levels in the prevention of death from COVID-19 in the ICU.